Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide
Open Access
- 31 January 2007
- journal article
- Published by Elsevier BV in Nuclear Medicine and Biology
- Vol. 34 (1), 29-35
- https://doi.org/10.1016/j.nucmedbio.2006.10.006
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Multimodality Imaging of Tumor Integrin αvβ3 ExpressionMini-Reviews in Medicinal Chemistry, 2006
- Radiolabeled Tracers for Imaging of Tumor Angiogenesis and Evaluation of Anti-Angiogenic TherapiesCurrent Pharmaceutical Design, 2004
- Peptide‐based radiopharmaceuticals: Future tools for diagnostic imaging of cancers and other diseasesMedicinal Research Reviews, 2004
- Comparison of a Monomeric and Dimeric Radiolabeled RGD-Peptide for Tumor TargetingCancer Biotherapy & Radiopharmaceuticals, 2002
- Ligand Binding to IntegrinsJournal of Biological Chemistry, 2000
- Expression of vascular endothelial growth factor in lymphomas and castleman's diseaseThe Journal of Pathology, 1997
- Stereoisomeric Peptide Libraries and Peptidomimetics for Designing Selective Inhibitors of the αvβ3 Integrin for a New Cancer TherapyAngewandte Chemie-International Edition, 1997
- Role of integrins in angiogenesisEuropean Journal Of Cancer, 1996
- Angiogenesis in cancer, vascular, rheumatoid and other diseaseNature Medicine, 1995
- Integrins: Versatility, modulation, and signaling in cell adhesionCell, 1992